文献速递淋巴瘤

优化晚期霍奇金淋巴瘤的治疗

Optimizing therapy in advanced-stage Hodgkin lymphoma.
PubMed 文献 · Blood · 2018-03-02

本文综述了霍奇金淋巴瘤治疗从扩大野放疗到联合化疗、风险适应和反应适应调整、抗体药物偶联物及免疫检查点阻断抗体的演变,治愈率逐步提高,10年生存率现已超过80%。当前挑战在于在维持或改善生存质量的同时避免治疗不足或过度治疗,年龄是重要因素,风险与反应适应相结合可能是理想策略。

要点

  • 霍奇金淋巴瘤10年生存率现已超过80%,而40年前低于50%。
  • 治疗已从基于基线特征的风险适应转向结合功能影像早期评估疗效的反应适应。
  • 60岁以上患者结局改善程度未及60岁以下人群,反映需要不同策略。

核心结论

  • 霍奇金淋巴瘤治疗演变使治愈率逐步提高,10年生存率现已超过80%,而40年前低于50%。
  • 当前挑战在于如何在成功基础上维持或改善幸存者生活质量,在治疗不足与过度治疗之间取得平衡依然复杂。
  • 多项试验结果表明反应适应治疗具有优势,但风险与反应适应相结合可能是理想策略。

研究设计与样本

  • 本文为综述,回顾了霍奇金淋巴瘤治疗从20世纪60年代扩大野放疗到受累野及受累淋巴结放疗、多药化疗、联合放化疗、风险适应和反应适应调整,以及近期抗体药物偶联物和免疫检查点阻断抗体引入的演变。

主要发现

  • 霍奇金淋巴瘤10年生存率现已超过80%,而40年前低于50%。
  • 60岁以上患者结局改善速度未及60岁以下人群,反映需要不同方法。
  • 治疗已从主要基于解剖分期和疾病严重程度等基线特征的风险适应,转向利用功能影像早期评估疗效并调整后续治疗的反应适应动态方法。
  • 多项试验结果表明反应适应治疗具有优势,但风险与反应适应相结合可能是理想策略。

关键数值与推荐

  • 10年生存率现已超过80%,而40年前低于50%。

临床怎么用

  • 治疗已从主要基于风险转向更动态的、考虑治疗反应的方法,利用功能影像进行早期评估并调整后续治疗。
  • 多项试验结果表明反应适应治疗具有优势,但风险与反应适应相结合可能是理想策略。
  • 60岁以上患者结局改善未及60岁以下人群,反映需要不同方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of Hodgkin lymphoma has evolved continuously since the introduction of extended-field radiotherapy in the 1960s to involved-field and then involved-node radiotherapy, multiagent chemotherapy, combined chemoradiotherapy, risk-adapted and response-adapted modulation, and, most recently, introduction of antibody-drug conjugates and immune checkpoint-blocking antibodies. These changes have translated into progressively increasing cure rates, so that 10-year survival figures now exceed 80%, compared with <50% 40 years ago. The challenge now is how to improve upon success while maintaining, or if possible improving, the quality of life for survivors. Steering between undertreatment, with the risk of avoidable recurrences, and overtreatment, with the risk of unnecessary toxicity, remains complex because control of the lymphoma and the probability of survival are no longer closely linked. This requires trials with long follow-up and continuous reappraisal of the interaction between the illness; the method used to define risk, and the type of treatment involved. One important factor in this is age: outcomes in older patients have not improved at the same rate as those in the population under 60 years of age, reflecting the need for different approaches. Recently, treatment has moved from being primarily risk-based, using baseline characteristics such as anatomical stage and severity of the illness, to a more dynamic approach that takes account of the response to therapy, using functional imaging to make an early appraisal, with the option to modulate subsequent treatment. The results of several trials indicate that this has advantages, but a combination of risk- and response-adaptation is probably ideal.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood. 2018. PMID: 29500173. doi:10.1182/blood-2017-09-772640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。